Integrative Analysis of Public Chip-Seq Experiments Reveals a Complex Multi-Cell Regulatory Landscape
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Two Regions Within the Proximal Steroidogenic Factor 1 Promoter Drive Somatic Cell-Specific Activity in Developing Gonads of the Female Mouse1
BIOLOGY OF REPRODUCTION 84, 422–434 (2011) Published online before print 20 October 2010. DOI 10.1095/biolreprod.110.084590 Two Regions Within the Proximal Steroidogenic Factor 1 Promoter Drive Somatic Cell-Specific Activity in Developing Gonads of the Female Mouse1 Liying Gao,4 Youngha Kim,7 Bongki Kim,3,5,7 Stacey M. Lofgren,8 Jennifer R. Schultz-Norton,9 Ann M. Nardulli,6 Leslie L. Heckert,10 and Joan S. Jorgensen2,7 Departments of Veterinary Biosciences,4 Animal Sciences,5and Molecular and Integrative Physiology,6 University of Illinois at Urbana-Champaign, Urbana, Illinois Department of Comparative Biosciences,7 University of Wisconsin, Madison, Wisconsin IVF Institute of Chicago,8 Chicago, Illinois Department of Biology,9 Millikin University, Decatur, Illinois Department of Molecular and Integrative Physiology,10 University of Kansas Medical Center, Kansas City, Kansas ABSTRACT adrenal 4-binding protein (AD4BP), is a transcription factor that is a member of the nuclear hormone receptor family [1, 2]. Targets of steroidogenic factor 1 (SF1; also known as NR5A1 Disruption of Sf1 in mice results in adrenal and gonad agenesis and AD4BP) have been identified within cells at every level of the in both sexes, thereby implicating it in early organogenesis [3– hypothalamic-pituitary-gonadal and -adrenal axes, revealing SF1 5]. These organs form normally at first but then disappear to be a master regulator of major endocrine systems. Mouse because of increased cell death by apoptosis, demonstrating a embryos express SF1 in the genital ridge until Embryonic Day 13.5 key role for SF1 in cell survival [3]. Haploinsufficiency of SF1 (E13.5). -
Stroke Genetics and Genomics
Faculdade de Medicina da Universidade de Lisboa Unidade Neurológica de Investigação Clínica PhD Thesis Stroke Genetics and Genomics Tiago Krug Coelho Host Institution: Instituto Gulbenkian de Ciência Supervisor at Instituto Gulbenkian de Ciência: Doctor Sofia Oliveira Supervisor at Faculdade de Medicina da Universidade de Lisboa: Professor José Ferro PhD in Biomedical Sciences Specialization in Neurosciences 2010 Stroke Genetics and Genomics A ciência tem, de facto, um único objectivo: a verdade. Não esgota perfeitamente a sua tarefa se não descobre a causa do todo. Chiara Lubich i Stroke Genetics and Genomics ii Stroke Genetics and Genomics A impressão desta dissertação foi aprovada pela Comissão Coordenadora do Conselho Científico da Faculdade de Medicina de Lisboa em reunião de 28 de Setembro de 2010. iii Stroke Genetics and Genomics iv Stroke Genetics and Genomics As opiniões expressas são da exclusiva responsabilidade do seu autor. v Stroke Genetics and Genomics vi Stroke Genetics and Genomics Abstract ABSTRACT This project presents a comprehensive approach to the identification of new genes that influence the risk for developing stroke. Stroke is the leading cause of death in Portugal and the third leading cause of death in the developed world. It is even more disabling than lethal, and the persistent neurological impairment and physical disability caused by stroke have a very high socioeconomic cost. Moreover, the number of affected individuals is expected to increase with the current aging of the population. Stroke is a “brain attack” cutting off vital blood and oxygen to the brain cells and it is a complex disease resulting from environmental and genetic factors. -
Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges
cancers Review Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges Dimitrios Doultsinos 1,* and Ian G. Mills 1,2 1 Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK; [email protected] 2 Patrick G Johnston Centre for Cancer Research, Queen’s University of Belfast, Belfast BT9 7AE, UK * Correspondence: [email protected] Simple Summary: Prostate cancer continues to exert a significant public health burden across the globe with hundreds of thousands of new diagnoses per year. There have been many advances in prostate cancer treatment that have dramatically improved the outlook for a lot of patients, especially by targeting a key factor in prostate cancer development called the androgen receptor. However, with increasing of targeted therapies we see a shift in the spectrum of treatment resistance disease. Molecular signatures are essentially maps of the potential for tumor evolution. By analyzing patient and pre-clinical model derived data, we may put together lists of genetic determinants of cancer progression and predict if patients will be prone to develop aggressive disease. In this manuscript we are reviewing some of the ways that these signatures are generated and discuss the advantages and disadvantages of their utility in personalized medicine. Abstract: Prostate cancer is a high-incidence cancer that requires improved patient stratification to ensure accurate predictions of risk and treatment response. Due to the significant contributions Citation: Doultsinos, D.; Mills, I.G. of transcription factors and epigenetic regulators to prostate cancer progression, there has been Derivation and Application of considerable progress made in developing gene signatures that may achieve this. -
Prolactin and Oestrogen Synergistically Regulate Gene Expression and Proliferation of Breast Cancer Cells
Endocrine-Related Cancer (2010) 17 809–822 Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells Louise Maymann Rasmussen1,2, Klaus Stensgaard Frederiksen1, Nanni Din 1, Elisabeth Galsgaard1, Leif Christensen1, Martin Werner Berchtold 2 and Svetlana Panina1 1Biopharmaceutical Research Unit, Novo Nordisk A/S, Novo Nordisk Park G8.1.55, Maaloev DK-2760, Denmark 2Department of Biology, University of Copenhagen, Copenhagen DK-2200, Denmark (Correspondence should be addressed to S Panina; Email: [email protected]) Abstract The pituitary hormone prolactin (PRL) plays an important role in mammary gland development. It was also suggested to contribute to breast cancer progression. In vivo data strongly supported a crucial role of PRL in promoting tumour growth; however, PRL demonstrated only a weak, if any, pro-proliferative effect on cancer cells in vitro. Several recent studies indicated that PRL action in vivo may be influenced by the hormonal milieu, e.g. other growth factors such as 17b-oestradiol (E2). Here, we explored the potential interplay between PRL and E2 in regulation of gene expression and cell growth. PRL alone induced either a weak or no proliferative response of T47D and BT-483 cells respectively, while it drastically enhanced cell proliferation in E2-stimulated cultures. Affymetrix microarray analysis revealed 12 genes to be regulated by E2, while 57 genes were regulated by PRL in T47D cells. Most of the PRL-regulated genes (42/57) were not previously described as PRL target genes, e.g. WT1 and IER3. One hundred and five genes were found to be regulated upon PRL/E2 co-treatment: highest up-regulation was found for EGR3, RUNX2, EGR1, MAFF, GLIPR1, IER3, SOCS3, WT1 and AREG. -
Atlas Journal
Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 12, Number 6, Nov-Dec 2008 Previous Issue / Next Issue Genes BCL8 (B-cell CLL/lymphoma 8) (15q11). Silvia Rasi, Gianluca Gaidano. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 781-784. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/BCL8ID781ch15q11.html CDC25A (Cell division cycle 25A) (3p21). Dipankar Ray, Hiroaki Kiyokawa. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 785-791. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CDC25AID40004ch3p21.html CDC73 (cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)) (1q31.2). Leslie Farber, Bin Tean Teh. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 792-797. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/CDC73D181ch1q31.html EIF3C (eukaryotic translation initiation factor 3, subunit C) (16p11.2). Daniel R Scoles. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 798-802. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/EIF3CID44187ch16p11.html ELAC2 (elaC homolog 2 (E. coli)) (17p11.2). Yang Chen, Sean Tavtigian, Donna Shattuck. Atlas Genet Cytogenet Oncol Haematol 2008; 12 (6): 803-806. [Full Text] [PDF] URL : http://atlasgeneticsoncology.org/Genes/ELAC2ID40437ch17p11.html FOXM1 (forkhead box M1) (12p13). Jamila Laoukili, Monica Alvarez Fernandez, René H Medema. -
Computational Discovery of Transcription Factors Associated with Drug Response
OPEN The Pharmacogenomics Journal (2016) 16, 573–582 www.nature.com/tpj ORIGINAL ARTICLE Computational discovery of transcription factors associated with drug response C Hanson1, J Cairns2, L Wang2 and S Sinha3 This study integrates gene expression, genotype and drug response data in lymphoblastoid cell lines with transcription factor (TF)-binding sites from ENCODE (Encyclopedia of Genomic Elements) in a novel methodology that elucidates regulatory contexts associated with cytotoxicity. The method, GENMi (Gene Expression iN the Middle), postulates that single-nucleotide polymorphisms within TF-binding sites putatively modulate its regulatory activity, and the resulting variation in gene expression leads to variation in drug response. Analysis of 161 TFs and 24 treatments revealed 334 significantly associated TF–treatment pairs. Investigation of 20 selected pairs yielded literature support for 13 of these associations, often from studies where perturbation of the TF expression changes drug response. Experimental validation of significant GENMi associations in taxanes and anthracyclines across two triple-negative breast cancer cell lines corroborates our findings. The method is shown to be more sensitive than an alternative, genome-wide association study-based approach that does not use gene expression. These results demonstrate the utility of GENMi in identifying TFs that influence drug response and provide a number of candidates for further testing. The Pharmacogenomics Journal (2016) 16, 573–582; doi:10.1038/tpj.2015.74; published online 27 October 2015 INTRODUCTION regulatory activities are associated with cellular response to The field of pharmacogenetics aims to understand the relationship cytotoxic treatments (Figure 1a), with the expectation that in the between individual variation at the genetic level and variation in future the response may be manipulated by intervening with the cellular or physiological response to a drug. -
Integrated Computational Approach to the Analysis of RNA-Seq Data Reveals New Transcriptional Regulators of Psoriasis
OPEN Experimental & Molecular Medicine (2016) 48, e268; doi:10.1038/emm.2016.97 & 2016 KSBMB. All rights reserved 2092-6413/16 www.nature.com/emm ORIGINAL ARTICLE Integrated computational approach to the analysis of RNA-seq data reveals new transcriptional regulators of psoriasis Alena Zolotarenko1, Evgeny Chekalin1, Alexandre Mesentsev1, Ludmila Kiseleva2, Elena Gribanova2, Rohini Mehta3, Ancha Baranova3,4,5,6, Tatiana V Tatarinova6,7,8, Eleonora S Piruzian1 and Sergey Bruskin1,5 Psoriasis is a common inflammatory skin disease with complex etiology and chronic progression. To provide novel insights into the regulatory molecular mechanisms of the disease, we performed RNA sequencing analysis of 14 pairs of skin samples collected from patients with psoriasis. Subsequent pathway analysis and extraction of the transcriptional regulators governing psoriasis-associated pathways was executed using a combination of the MetaCore Interactome enrichment tool and the cisExpress algorithm, followed by comparison to a set of previously described psoriasis response elements. A comparative approach allowed us to identify 42 core transcriptional regulators of the disease associated with inflammation (NFκB, IRF9, JUN, FOS, SRF), the activity of T cells in psoriatic lesions (STAT6, FOXP3, NFATC2, GATA3, TCF7, RUNX1), the hyper- proliferation and migration of keratinocytes (JUN, FOS, NFIB, TFAP2A, TFAP2C) and lipid metabolism (TFAP2, RARA, VDR). In addition to the core regulators, we identified 38 transcription factors previously not associated with the disease that can clarify the pathogenesis of psoriasis. To illustrate these findings, we analyzed the regulatory role of one of the identified transcription factors (TFs), FOXA1. Using ChIP-seq and RNA-seq data, we concluded that the atypical expression of the FOXA1 TF is an important player in the disease as it inhibits the maturation of naive T cells into the (CD4+FOXA1+CD47+CD69+PD-L1(hi) FOXP3 − ) regulatory T cell subpopulation, therefore contributing to the development of psoriatic skin lesions. -
Systems Biology Evaluation of Immune Responses Induced by Human Host Defence Peptide LL-37 in Mononuclear Cellsw
PAPER www.rsc.org/molecularbiosystems | Molecular BioSystems Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cellsw Neeloffer Mookherjee,za Pamela Hamill,a Jennifer Gardy,a Darren Blimkie,b Reza Falsafi,a Avinash Chikatamarla,a David J. Arenillas,c Silvana Doria,a Tobias R. Kollmannb and Robert E. W. Hancock*a Received 7th August 2008, Accepted 29th January 2009 First published as an Advance Article on the web 19th March 2009 DOI: 10.1039/b813787k The immune system is very complex, it involves the integrated regulation and expression of hundreds of proteins. To understand in greater detail how the human host defence immunomodulatory peptide LL-37 interacts with innate immunity, a systems approach was pursued. Polychromatic flow cytometry was employed to demonstrate that within human peripheral blood mononuclear cells, CD14+ monocytes, myeloid and plasmocytoid dendritic cells and T- and B-lymphocytes, all responded to LL-37, with the differential production of intracellular cytokines. Microarray analyses with CD14+ monocytes indicated the differential expression of 475 genes in response to stimulation with LL-37. To understand this complex response, bioinformatic interrogation, using InnateDB, of the gene ontology, signalling pathways and transcription factor binding sites was undertaken. Activation of the IkBa/NFkB, mitogen- activated protein kinases p38, ERK1/2 and JNK, and PI3K signalling pathways in response to LL-37 was demonstrated by pathway and ontology over-representation analyses, and confirmed experimentally by inhibitor studies. Computational analysis of the predicted transcription factor binding sites upstream of the genes that were regulated by LL-37 predicted the involvement of several transcription factors including NFkB and five novel factors, AP-1, AP-2, SP-1, E2F1, and EGR, which were experimentally confirmed to respond to LL-37 by performing transcription factor array studies on nuclear extracts from LL-37 treated mononuclear cells. -
Alternatively Constructed Estrogen Receptor Alpha-Driven Super-Enhancers Result in Similar Gene Expression in Breast and Endometrial Cell Lines
International Journal of Molecular Sciences Article Alternatively Constructed Estrogen Receptor Alpha-Driven Super-Enhancers Result in Similar Gene Expression in Breast and Endometrial Cell Lines 1,2, 3, 1, Dóra Bojcsuk y , Gergely Nagy y and Bálint László Bálint * 1 Genomic Medicine and Bioinformatic Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; [email protected] 2 Doctoral School of Molecular Cell and Immune Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary 3 Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; [email protected] * Correspondence: [email protected] These authors contributed equally to this work. y Received: 22 January 2020; Accepted: 25 February 2020; Published: 27 February 2020 Abstract: Super-enhancers (SEs) are clusters of highly active enhancers, regulating cell type-specific and disease-related genes, including oncogenes. The individual regulatory regions within SEs might be simultaneously bound by different transcription factors (TFs) and co-regulators, which together establish a chromatin environment conducting to effective transcription. While cells with distinct TF profiles can have different functions, how different cells control overlapping genetic programs remains a question. In this paper, we show that the construction of estrogen receptor alpha-driven SEs is tissue-specific, both collaborating TFs and the active SE components greatly differ between human breast cancer-derived MCF-7 and endometrial cancer-derived Ishikawa cells; nonetheless, SEs common to both cell lines have similar transcriptional outputs. These results delineate that despite the existence of a combinatorial code allowing alternative SE construction, a single master regulator might be able to determine the overall activity of SEs. -
Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham a Thesis Submitted in Conformity
Characterizing Genomic Duplication in Autism Spectrum Disorder by Edward James Higginbotham A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Molecular Genetics University of Toronto © Copyright by Edward James Higginbotham 2020 i Abstract Characterizing Genomic Duplication in Autism Spectrum Disorder Edward James Higginbotham Master of Science Graduate Department of Molecular Genetics University of Toronto 2020 Duplication, the gain of additional copies of genomic material relative to its ancestral diploid state is yet to achieve full appreciation for its role in human traits and disease. Challenges include accurately genotyping, annotating, and characterizing the properties of duplications, and resolving duplication mechanisms. Whole genome sequencing, in principle, should enable accurate detection of duplications in a single experiment. This thesis makes use of the technology to catalogue disease relevant duplications in the genomes of 2,739 individuals with Autism Spectrum Disorder (ASD) who enrolled in the Autism Speaks MSSNG Project. Fine-mapping the breakpoint junctions of 259 ASD-relevant duplications identified 34 (13.1%) variants with complex genomic structures as well as tandem (193/259, 74.5%) and NAHR- mediated (6/259, 2.3%) duplications. As whole genome sequencing-based studies expand in scale and reach, a continued focus on generating high-quality, standardized duplication data will be prerequisite to addressing their associated biological mechanisms. ii Acknowledgements I thank Dr. Stephen Scherer for his leadership par excellence, his generosity, and for giving me a chance. I am grateful for his investment and the opportunities afforded me, from which I have learned and benefited. I would next thank Drs. -
Sequence and Chromatin Determinants of Cell-Type Specific
Sequence and chromatin determinants of cell-type specific transcription factor binding: supplementary data Aaron Arvey1, Phaedra Agius1, William Stafford Noble2, and Christina Leslie1∗ 1Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 2Department of Genome Sciences, University of Washington, Seattle, WA March 15, 2012 Table S1: List of all TF ChIP-seq experiments analyzed in the study. File name Cell TF wgEncodeYaleChIPseqRawDataRep1Helas3Ap2alpha Helas3 AP2A1 wgEncodeYaleChIPseqRawDataRep2Helas3Ap2alpha Helas3 AP2A1 wgEncodeYaleChIPseqRawDataRep1Helas3Ap2gamma Helas3 TFAP2C wgEncodeYaleChIPseqRawDataRep2Helas3Ap2gamma Helas3 TFAP2C wgEncodeYaleChIPseqRawDataRep1K562Atf3 K562 ATF3 wgEncodeYaleChIPseqRawDataRep2K562Atf3 K562 ATF3 wgEncodeYaleChIPseqRawDataRep1Helas3Baf155Musigg Helas3 SMARCC1 wgEncodeYaleChIPseqRawDataRep2Helas3Baf155Musigg Helas3 SMARCC1 wgEncodeYaleChIPseqRawDataRep1Helas3Baf170Musigg Helas3 SMARCC2 wgEncodeHudsonalphaChipSeqRawDataRep1Gm12878Batf Gm12878 BATF wgEncodeHudsonalphaChipSeqRawDataRep2Gm12878Batf Gm12878 BATF wgEncodeHudsonalphaChipSeqRawDataRep1Gm12878Bcl11a Gm12878 BCL11A wgEncodeHudsonalphaChipSeqRawDataRep2Gm12878Bcl11a Gm12878 BCL11A wgEncodeHudsonalphaChipSeqRawDataRep1Gm12878Bcl3Pcr1xBcl3 Gm12878 BCL3 wgEncodeHudsonalphaChipSeqRawDataRep2Gm12878Bcl3Pcr1xBcl3 Gm12878 BCL3 wgEncodeYaleChIPseqRawDataRep1Helas3Bdp1 Helas3 BDP1 wgEncodeYaleChIPseqRawDataRep2Helas3Bdp1 Helas3 BDP1 wgEncodeYaleChIPseqRawDataRep1K562Bdp1 K562 BDP1 wgEncodeYaleChIPseqRawDataRep2K562Bdp1 K562